Newsroom - GILUPI GmbH

Press releases

GILUPI will attend at the ACTC congress in Rhodes

, Medical Technology

GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress. The 3rd ACTC meeting will...

In vivo detection of CTCs in head and neck cancer patients using the GILUPI CellCollector®

, Medical Technology

GILUPI GmbH announces the recent publication of a clinical study demonstrates the isolation of circulating tumor cells (CTCs) from blood of squamous...

Detection of circulating tumor cells in breast cancer patients using the GILUPI CellCollector®

, Medical Technology

GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the current issue of "National...

Approval for German Medical Device in China

, Medical Technology

The GILUPI CellCollector® - the first medical device for in vivo CTC isolation, manufactured by GILUPI - has been approved by the Chinese registrations...

Zulassung für Potsdamer Medizinprodukt in China

, Medical Technology

Der GILUPI CellCollector® - das erste zugelassene Medizinprodukt zur in vivo – Isolation von zirkulierenden Tumorzellen der Potsdamer GILUPI...

GILUPI extends its patent portfolio

, Medical Technology

GILUPI GmbH announced today that the company was granted a further Chinese patent protecting the unique and innovative GILUPI technology. The...

Improved detection of circulating tumor cells in prostate cancer patients using the GILUPI CellCollector® in combination with two blood-based assays

, Medical Technology

GILUPI GmbH announces the release of clinical data from a prostate cancer clinical study in December 2016. The scientific paper demonstrates...

Chinese Biotech Investor VIROAD takes over GILUPI

, Medical Technology

The investors AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, the - venture capital fund of the Sparkassen of Brandenburg and Business Angels...

Chinesischer Biotechnologie-Investor VIROAD übernimmt GILUPI

, Medical Technology

Die Investoren AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, der Risikokapitalfonds der Sparkassen des Landes Brandenburg und Business Angels...

GILUPI at the 17th World Conference on Lung Cancer

, Medical Technology

GILUPI will participate at the 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria. The WCLC is the world’s largest meeting dedicated...

GILUPI at the 6th Herbsttreffen AG Molekularpathologie

, Medical Technology

At the 6th Herbsttreffen AG Molekularpathologie in Karlsruhe, Germany, from 21th to 22th November 2016, GILUPI will be one of the exhibitors...

Enumeration and molecular characterization of circulating tumor cells in prostate cancer patients using the GILUPI CellCollector®

, Medical Technology

GILUPI GmbH announces the release of clinical data from a prostate cancer setting in August 2016. The scientific paper demonstrate the isolation...

Identification and enumeration of circulating tumor cells in neuroendocrine tumor patients with GILUPI CellCollector®

, Medical Technology

GILUPI GmbH announces, that in August 2016 a published scientific paper demonstrated for the first time circulating tumor cell (CTCs) isolation...

GILUPI GmbH Receives ISO 13485 Certification for Manufacturing and Distribution of Cell Separation Devices

, Medical Technology

After the 68th AACC Annual Scientific Meeting & Clinical Lab Expo (AACC), GILUPI GmbH announces that it has received EN ISO 13485 certification...

GILUPI Strengthens Executive Team - Appoints Dr. Jens Pfannkuche as General Manager

, Medical Technology

GILUPI GmbH, a developer and manufacturer of medical devices to enrich circulating tumor cells (CTCs) in the human blood stream, announces that...

Media

Loading data, please wait...
Loading data, please wait...
Loading data, please wait...
Loading data, please wait...
GILUPI GmbH
Hermannswerder 20a
D - 14473 Potsdam




Social Media Accounts

Contact

Frau Dr. Claudia Chudak


Marketing & Sales Application Specialist

Phone +49 331 5818478-5

all contacts

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.